Researchers in the Preston Robert Tisch Brain Tumor Center at Duke have identified a new therapeutic vulnerability in IDH-mutant astrocytomas and other gliomas.
One surgeon’s question is helping advance robotic brain surgery at Duke, which ranks No. 32 worldwide for U.S. utility patents
Duke study shows direct-to-tumor EGFR therapy can be safely delivered in glioblastoma
Researchers from Duke’s Preston Robert Tisch Brain Tumor Center have found that a therapy targeting the epidermal growth factor receptor (EGFR) can be safely delivered directly into recurrent glioblastomas and may improve patient outcomes.
Brick by brick, a Duke PhD student makes brain research easier to grasp
Bucklan is a second-year graduate student in the University Program in Genetics and Genomics, an interdisciplinary biomedical PhD program. He also works in the lab of Simon Gregory, PhD, the director of the Brain Tumor Omics Program in the Duke Department of Neurosurgery.
INDIGO Trial Insights: Patient Selection, Progression-Free Survival, and Tumor Control
Katherine B. Peters, MD, PhD, reviews the phase 3 INDIGO trial (NCT04164901), highlighting its patient population, significant progression-free survival benefit, and the impact of vorasidenib on delaying disease progression and need for further intervention.
Duke Researchers Identify Potential New Weakness in Glioma Brain Tumors
Researchers in the lab of Matthew Waitkus, PhD, at the Preston Robert Tisch Brain Tumor Center have identified a promising new target for treating certain brain tumors, including IDH-mutant astrocytomas.
Waitkus Lab identifies a new therapeutic vulnerability for brain tumors
Researchers in the Preston Robert Tisch Brain Tumor Center at Duke have identified a new therapeutic vulnerability in IDH-mutant astrocytomas and other gliomas.
Duke Launches Phase 1 Trial Evaluating FDA Breakthrough Device for Real-Time Monitoring of Recurrent Glioblastoma
Researchers at the Preston Robert Tisch Brain Tumor Center at Duke have enrolled the first patients in a Phase 1 clinical trial evaluating a novel FDA Breakthrough Device designed to safely monitor recurrent glioblastoma in real time.
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021 the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors.
Mustafa Khasraw to Lead U.S. Arm of International Glioblastoma Trial
Mustafa Khasraw, MD, deputy director of the Duke Cancer Institute Center for Cancer Immunotherapy, is at the forefront of a promising clinical trial aimed at improving outcomes for patients with glioblastoma.